Related Experiment Video
Updated: Jun 20, 2026

Surgical Approach and Complications of Stand-alone Lateral Trans-Psoas Interbody Fusion
Published on: February 14, 2025
Comparable Survivorship and Patient-Reported Outcomes Following Unicompartmental Knee Arthroplasty in Obese and
Michelle Cruickshank1, Helena Son1, Hassaan Abdel Khalik2
1Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Background:
The influence of obesity on outcomes after unicompartmental knee arthroplasty (UKA) remains controversial. This systematic review evaluated whether obesity affects survivorship, reasons for revision, and patient-reported outcome measures (PROMs) following UKA.
Methods:
MEDLINE, EMBASE, and CENTRAL were searched from inception to October 15, 2025. Eligible studies reported UKA outcomes stratified by body mass index (BMI), including cohorts exclusively composed of obese patients (BMI ≥ 30). Less than 5-year), five to less than 10-year, and ≥ 10-year survivorship was compared across nonobese (BMI less than 30), obese (BMI 30 to less than 40), and morbidly obese (BMI ≥ 40) patients using meta-analysis. Secondary outcomes included reasons for revision and PROMs. There were 27 studies (27,271 knees) included (mean age, 65 years; mean BMI, 30.7).
Results:
Less than 5-year survivorship for nonobese, obese, and morbidly obese groups was 95.5, 95.3, and 95.8%, respectively (P = 0.943). The five to less than 10-year survivorship was 95.3, 92.1, and 90.6%, respectively (P = 0.034), with adjusted pairwise comparison demonstrating a nonsignificant trend toward lower survivorship in morbidly obese patients compared to nonobese (adjusted P = 0.065). The ≥ 10-year survivorship was 92.1, 92.9, and 88.7%, respectively (P = 0.460). The most common causes for revision were aseptic loosening (47.0%), pain without loosening (16.2%), and progression of osteoarthritis (15.2%). Morbidly obese patients demonstrated higher rates of progressive osteoarthritis and technique-related failure. The PROMs improved across all BMI categories, with slightly lower scores in obese and morbidly obese individuals.
Conclusions:
Obesity should not be considered an absolute contraindication to UKA. Obese patients achieve substantial functional improvement and demonstrate survivorship comparable to nonobese patients across less than 5-years, five to less than 10-years, and ≥ 10-years follow-up. Morbidly obese patients more often required secondary surgery for progression of arthritis, a modifiable risk factor that can inform individualized preoperative counseling and risk mitigation strategies.
Level Of Evidence:
IV.
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Drug Dosing: Obese Patients
Obesity